A 2003 study by Staresinic, Sebecic, Patrlj, and colleagues in Journal of Orthopaedic Research used a rat Achilles tendon transection model with BPC-157 administered intraperitoneally once daily at 10 g/kg, 10 ng/kg, or 10 pg/kg and reported improved load-to-failure, Young's modulus of elasticity, and Achilles functional index scores, reduced tendon defect size by day 14, and increased tendocyte outgrowth in vitro with specific numerical effect sizes and p-values not reported in the abstract
Gupta G, Gliga A, Hedberg J, Serra A, Greco D, Odnevall Wallinder I, et al
, Wang Q., Lin S., et al
Healthy-Aging & Physiological-Resilience Research Ipamorelin is also commonly researched in: Healthy-aging pathway investigations Physiological-resilience research Recovery-focused metabolic signaling Cellular-maintenance pathways Neuroendocrine-related physiological mechanisms Metabolic & Cellular-Energy Research Research models involving Ipamorelin commonly investigate: Metabolic-signaling pathways Cellular-energy mechanisms Recovery-focused metabolic pathways Body-composition signaling Physiological-maintenance pathways Because Ipamorelin stimulates endogenous GH-release pathways, research commonly investigates broader interaction with metabolic, recovery-focused, and physiological-resilience signaling pathways
Its mechanism involves specific engagement of AMY1R and AMY3R in hindbrain and hypothalamic circuits that regulate energy homeostasis, leading to preferential fat mass reduction and altered hypothalamic gene expression profiles [2]
